Risk of Meningioma in European Patients Treated With Growth Hormone in Childhood: Results From the SAGhE Cohort

Abstract

Our data add to evidence of very high risk of meningioma in patients treated in childhood with GH after cranial radiotherapy, but suggest that GH may not affect radiotherapy-related risk, and that there is no material raised risk of meningioma in GH-treated patients who did not receive radiotherapy.